Are statins a treatment option for multiple sclerosis? (Q35781154)

10 August 2017

1 reference

title

Are statins a treatment option for multiple sclerosis? (English)

1 reference

10 August 2017

0 references

Hans-Peter Hartung

1 reference

10 August 2017

Olaf Stüve

1 reference

10 August 2017

Oliver Neuhaus

1 reference

10 August 2017

Scott S Zamvil

series ordinal

1 reference

10 August 2017

publication date

1 June 2004

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

page(s)

369-371

1 reference

New concepts in the immunopathogenesis of multiple sclerosis

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

New and emerging treatment options for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Safety and statin therapy: reconsidering the risks and benefits

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Role of mevalonic acid in the regulation of natural killer cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Statins as anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Potential of statins for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Therapeutic potential of lovastatin in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

The IL-1 receptor and Rho directly associate to drive cell activation in inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

Multiple sclerosis: a two-stage disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900770-7

7 January 2021

10.1016/S1474-4422(04)00770-7

Identifiers

DOI

1 reference

10 August 2017

1 reference